Brought to you by 
Quark gets access to Alnylam's InterfeRx program
18 Mar 2011
Executive Summary
Quark Biotech (creating treatments for fibrotic and ischemic conditions in the eyes, kidney, and lungs) has received rights to use Alnylam Pharmaceuticals's (developing RNAi drug candidates for respiratory, neurological, cardiovascular, and musculoskeletal conditions and infectious diseases) RNAi patents--through the InterfeRx licensing program--to discover, develop, and market RNAi therapeutics that target p53 and RTP801 genes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Quark gets access to Alnylam's InterfeRx program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice